Roche's Giredestrant Success: Cutting Breast Cancer Recurrence Risk
Roche’s experimental SERD, giredestrant, showed unprecedented success in a late-stage trial, cutting recurrence risk in early-stage, ER-positive breast cancer.
/ 2 items
Roche’s experimental SERD, giredestrant, showed unprecedented success in a late-stage trial, cutting recurrence risk in early-stage, ER-positive breast cancer.
Despite positive palazestrant (OP-1250) trial results, Olema Pharmaceuticals' shares dropped Monday, overshadowed by disappointing outcomes from a Roche breast cancer study.